Downloads: 0

Files in This Item:
This article will be available after a certain embargo period.
Please see the "Rights" information in item metadata display about embargo date.
Title: 去勢抵抗性前立腺癌に対するカバジタキセル療法の治療成績とサルコペニアとの関連についての検討
Other Titles: The Relationship between Sarcopenia and Survival after Cabazitaxel Treatment for Castration-Resistant Prostate Cancer
Authors: 大西, 健太  KAKEN_name
田中, 宣道  KAKEN_name
堀, 俊太  KAKEN_name
中井, 靖  KAKEN_name
三宅, 牧人  KAKEN_name
穴井, 智  KAKEN_name
藤本, 清秀  KAKEN_name
Author's alias: ONISHI, Kenta
TANAKA, Nobumichi
HORI, Shunta
NAKAI, Yasushi
MIYAKE, Makito
ANAI, Satoshi
FUJIMOTO, Kiyohide
Keywords: Castration-resistant prostate cancer
Issue Date: 31-Jul-2022
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 68
Issue: 7
Start page: 217
End page: 225
Abstract: Sarcopenia is a known predictor of overall survival in several diseases. We investigated the relationship between sarcopenia and outcome of treatment with cabazitaxel (CBZ) for castration-resistant prostate cancer (CRPC) by a retrospective analysis of 37 patients, who were given cabazitaxel at our hospital, from December 2014 to November 2020. The skeletal muscle mass was evaluated using the Psoas Muscle Mass Index (PMI: psoas major muscle area at the level of the third lumber vertebra (cm²)/height x height (m²)) through computed tomography images. The severe sarcopenia group (PMI<4.96) showed lower levels of serum albumin, in comparison with the non-severe sarcopenia group (PMI≥4.96). Multivariate analysis identified PMI (odds ratio=3.7; P=0.023) as an independent factor associated with prostate specific antigen response to CBZ therapy. However, there was no significant difference in the overall survival between the severe and the non-severe sarcopenia groups (P=0.1). Skeletal muscle mass might be closely correlated to the therapeutic response to CBZ, but not to the prognosis of patients with CRPC. Nutritional rehabilitation and exercises targeting sarcopenia for patients with prostate cancer should be considered.
Description: 本論文の要旨は,第109回日本泌尿器科学会総会で発表を行った.
Rights: 許諾条件により本文は2023/08/01に公開
DOI: 10.14989/ActaUrolJap_68_7_217
PubMed ID: 35924704
Appears in Collections:Vol.68 No.7

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.